{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:51:11Z","timestamp":1790070671513,"version":"4.0.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:00:00Z","timestamp":1599609600000},"content-version":"am","delay-in-days":436,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.lpm.2019.07.019","type":"journal-article","created":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T18:02:00Z","timestamp":1566496920000},"page":"807-815","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"P1","title":["La leuc\u00e9mie lympho\u00efde chronique\u00a0: mise au point"],"prefix":"10.1016","volume":"48","author":[{"given":"Nathalie","family":"Jacque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Leblond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2019.07.019_bib0005","series-title":"Estimation nationale de l\u2019incidence des cancers en France entre 1980\u00a0et 2012. Partie 2 \u2013 H\u00e9mopathies malignes","first-page":"88","author":"Monnereau","year":"2013"},{"key":"10.1016\/j.lpm.2019.07.019_bib0010","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Worshop on chronic lymphocytic leukemia updating the National Cancer Institute-Working Group 1996\u00a0guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2019.07.019_bib0015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3109\/10428199409052666","article-title":"The value of scoring systems for the diagnosis of biphenotypic leukemia and mature B-cell disorders","volume":"13","author":"Matutes","year":"1994","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.lpm.2019.07.019_bib0020","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.lpm.2019.07.019_bib0025","series-title":"59th Annual American Society of Hematology Meeting","article-title":"Incidence and type of opportunistic infections during Ibrutinib treatment at a single academic center #830","author":"Rogers","year":"2017"},{"key":"10.1016\/j.lpm.2019.07.019_bib0030","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1182\/blood.V128.22.637.637","article-title":"Venetoclax (VEN) monotherapy for patients with CLL who relapse after of were refractory to ibrutinib or idelalisib","volume":"128","author":"Jones","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2019.07.019_bib0035","series-title":"Survie des personnes atteintes de cancer en France m\u00e9tropolitaine, 1989\u20132013. Partie 2 \u2013 H\u00e9mopathies malignes","first-page":"144","author":"Monnereau","year":"2016"},{"issue":"2","key":"10.1016\/j.lpm.2019.07.019_bib0040","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.lpm.2019.07.019_bib0045","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2019.07.019_bib0050","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/leu.2015.14","article-title":"Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11\u00a0study","volume":"29","author":"Goede","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.lpm.2019.07.019_bib0055","article-title":"Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: final survival analysis of the cll11\u00a0study","author":"Goede","year":"2018","journal-title":"EHA"},{"key":"10.1016\/j.lpm.2019.07.019_bib0060","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2019.07.019_bib0065","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus of atumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2019.07.019_bib0070","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2019.07.019_bib0075","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory CLL with 17p deletion","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lpm.2019.07.019_bib0080","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/leu.2013.334","article-title":"Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA multi-center phase II trial","volume":"28","author":"Cortelezzi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.lpm.2019.07.019_bib0085","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1182\/blood.V124.21.3341.3341","article-title":"Bendamustine, ofatumumab and high-dose methylprednisolone (BOMP) in relapsed\/refractory CLL: results of a planned interim analysis of the french CLL intergroup ICLL01\u00a0phase II trial","volume":"124","author":"deGuibert","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2019.07.019_bib0090","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen eceptor-modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"JCO"},{"key":"10.1016\/j.lpm.2019.07.019_bib0095","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.3109\/10428194.2014.898758","article-title":"The impact of race, ethnicity, age, and sex on clinical outcome in chronic lymphocytic leukemia: a comprehensive SEER analysis in the modern era","volume":"55","author":"Nabhan","year":"2014","journal-title":"Leukemia Lymphoma"},{"key":"10.1016\/j.lpm.2019.07.019_bib0100","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1002\/cncr.25292","article-title":"Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia","volume":"116","author":"Shanafelt","year":"2010","journal-title":"Cancer"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498219303094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498219303094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:05:09Z","timestamp":1760105109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498219303094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":20,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0755498219303094"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2019.07.019","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"La leuc\u00e9mie lympho\u00efde chronique\u00a0: mise au point","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2019.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}